tumor infiltrating lymphocytes
GPTKB entity
Statements (78)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Cell
|
| gptkbp:are_derived_from |
peripheral blood lymphocytes
|
| gptkbp:associated_with |
tumor progression
|
| gptkbp:can_be |
activated by tumor antigens
expanded ex vivo for therapeutic use measured in tumor biopsies |
| gptkbp:can_be_modulated_by |
therapeutic agents
|
| gptkbp:can_be_used_in |
adoptive cell transfer therapy
|
| gptkbp:can_create |
cytokines
activation markers |
| gptkbp:can_detect |
immunohistochemistry
|
| gptkbp:components |
tumor-infiltrating immune cells
|
| gptkbp:enhances |
antitumor immunity
|
| gptkbp:exhibits |
heterogeneity
functional exhaustion |
| gptkbp:function |
target and destroy cancer cells
|
| gptkbp:has_a_focus_on |
cancer research
|
| gptkbp:has_role |
gptkb:immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
tumor infiltrating lymphocytes
|
| gptkbp:influence |
patient prognosis
|
| gptkbp:interacts_with |
other immune cells
|
| gptkbp:is_affected_by |
chemotherapy
|
| gptkbp:is_analyzed_in |
gene expression profiles
functional assays |
| gptkbp:is_associated_with |
immune-related adverse events
better clinical outcomes in some cancers specific tumor types |
| gptkbp:is_characterized_by |
T cell receptor diversity
cytokine profiles exhaustion markers high levels of PD-1 expression memory T cell markers metabolic profiles phenotypic markers |
| gptkbp:is_essential_for |
personalized cancer therapy
tumor rejection |
| gptkbp:is_found_in |
tumor microenvironment
|
| gptkbp:is_influenced_by |
environmental factors
nutritional status genetic factors radiation therapy hormonal factors microbiome composition systemic therapies tumor microenvironment factors tumor-derived factors |
| gptkbp:is_involved_in |
adaptive immune response
immune checkpoint blockade tumor surveillance tumor escape mechanisms immune evasion strategies tumor microenvironment remodeling tumor antigen recognition tumor immunoediting tumor-associated angiogenesis tumor-associated fibrosis tumor-associated immune dysregulation tumor-associated immune suppression tumor-associated immune tolerance tumor-associated inflammation tumor-associated lymphangiogenesis |
| gptkbp:is_studied_in |
biomarker discovery
clinical trials therapeutic efficacy clinical applications cancer immunology preclinical models treatment response prediction |
| gptkbp:is_targeted_at |
checkpoint inhibitors
|
| gptkbp:migration |
tumor sites
|
| gptkbp:occurs_in |
clonal expansion
|
| gptkbp:replaces |
tumor samples
|
| gptkbp:scientific_classification |
CD4+ and CD8+ T cells
|
| gptkbp:targets |
novel therapies
|
| gptkbp:type |
gptkb:T_cells
|
| gptkbp:bfsParent |
gptkb:PDCD1
gptkb:PD-L2 |
| gptkbp:bfsLayer |
7
|